Tian X X, Chan J Y, Pang J C, Chen J, He J H, To T S, Leung S F, Ng H K
Department of Anatomical and Cellular Pathology, Sir YK Pao Centre for Cancer, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, China.
Br J Cancer. 1999 Nov;81(6):994-1001. doi: 10.1038/sj.bjc.6690798.
Gene amplification and enhanced expression of the epidermal growth factor receptor (EGFR) represent the major molecular genetic alteration in glioblastomas and it may play an essential role in cell growth and in the carcinogenic process. On the other hand, the nuclear suppressor proteins PML and p53 are also known to play critical roles in cancer development and in suppressing cell growth. Here we report that, in glioblastoma cells with defective EGFR function, the expressions of both promyelocytic leukaemia (PML) and p53 were altered. Cells that were transfected with the antisense-cDNA of EGFR were found to have more cells in G1 and fewer cells in S phase. In addition, the transfected cells were found to be non-responsive to EGF-induced cell growth. Interestingly, the expression of the suppressors p53 and PML were found to be significantly increased by immunohistochemical assay in the antisense-EGFR cells. Moreover, the PML expression in many of the cells was converted from the nuclear dot pattern into fine-granulated staining pattern. In contrast, the expressions of other cell cycle regulated genes and proto-oncogene, including the cyclin-dependent kinase 4 (cdk4), retinoblastoma, p16INK4a and p21H-ras, were not altered. These data indicate that there are specific inductions of PML and p53 proteins which may account for the increase in G1 and growth arrest in antisense-EGFR treated cells. It also indicates that the EGF, p53 and PML transduction pathways were linked and they may constitute an integral part of an altered growth regulatory programme. The interactions and cross-talks of these critical molecules may be very important in regulating cell growth, differentiation and cellular response to treatment in glioblastomas.
基因扩增和表皮生长因子受体(EGFR)的表达增强是胶质母细胞瘤的主要分子遗传学改变,其可能在细胞生长和致癌过程中发挥重要作用。另一方面,核抑制蛋白PML和p53在癌症发展和抑制细胞生长中也发挥关键作用。在此我们报告,在EGFR功能缺陷的胶质母细胞瘤细胞中,早幼粒细胞白血病(PML)和p53的表达均发生改变。发现用EGFR反义cDNA转染的细胞G1期细胞更多,S期细胞更少。此外,发现转染细胞对表皮生长因子诱导的细胞生长无反应。有趣的是,通过免疫组织化学分析发现反义EGFR细胞中抑制因子p53和PML的表达显著增加。此外,许多细胞中的PML表达从核点状模式转变为细颗粒状染色模式。相比之下,其他细胞周期调节基因和原癌基因的表达,包括细胞周期蛋白依赖性激酶4(cdk4)、视网膜母细胞瘤、p16INK4a和p21H-ras,均未改变。这些数据表明,PML和p53蛋白存在特异性诱导,这可能解释了反义EGFR处理细胞中G1期增加和生长停滞的现象。这也表明表皮生长因子、p53和PML转导途径相互关联,它们可能构成改变的生长调节程序的一个组成部分。这些关键分子之间的相互作用和相互影响在调节胶质母细胞瘤的细胞生长、分化及细胞对治疗的反应方面可能非常重要。